Alosetron

BreastfeedingGeriatricPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Apomorphine, Conivaptan, CYP1A2 inhibitors, CYP3A4 inhibitors, Darunavir, Delavirdine, Eluxadoline, Fluvoxamine, Indinavir, Telithromycin, Teriflunomide, Voriconazole

PREGNANCY CATEGORY: B

Alosetron was approved in 2000 for use in women with diarrhea-predominant irritable bowel syndrome (IBS-D), however infrequent serious adverse events (including ischemic colitis and serious complications of constipation, resulting in hospitalization, blood transfusion, surgery and death) prompted alosetron's voluntary withdrawal from the US market in November 2000. Public request prompted its reintroduction in 2002 under a Risk Management Plan, including a more restricted indication and a Prescribing Program for Lotronex.

Only licensed for use in female patients.

Contra-indicated in patients with constipation or a history of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn’s disease or ulcerative colitis; diverticulitis; severe hepatic impairment.

SERIOUS GASTROINTESTINAL ADVERSE REACTIONS

See full prescribing information for complete boxed warning.

Our database has 33 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 09/03/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top